Search research articles
Contact Us
Filters
Showing results (71-80 of 204) with videos related to
Page
of 21
Sort By:
Journal of Crohn'S & Colitis
|
January 13, 2025
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases
|
June 28, 2022
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Inflammatory Bowel Diseases
|
May 15, 2023
Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
The American Journal of Gastroenterology
|
January 18, 2024
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
April 18, 2022
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Canadian Journal of Gastroenterology & Hepatology
|
July 12, 2014
Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review
Neeraj Narula, Diana Ulic, Raed Al-Dabbagh, et al.
Inflammatory Bowel Diseases
|
November 24, 2025
Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
Digestive Diseases and Sciences
|
January 16, 2023
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
September 6, 2022
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study
Neeraj Narula, Emily C L Wong, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 28, 2025
Week 12 Reduction in MM-SES-CD is Predictive of Delayed Response to Upadacitinib in Crohn's disease
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
Page
of 21
Search research articles
Search
Showing results (71-80 of 204) with videos related to
Sort By:
Page
of 21
Journal of Crohn'S & Colitis
|
January 13, 2025
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases
|
June 28, 2022
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Inflammatory Bowel Diseases
|
May 15, 2023
Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
The American Journal of Gastroenterology
|
January 18, 2024
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
April 18, 2022
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Canadian Journal of Gastroenterology & Hepatology
|
July 12, 2014
Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review
Neeraj Narula, Diana Ulic, Raed Al-Dabbagh, et al.
Inflammatory Bowel Diseases
|
November 24, 2025
Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
Digestive Diseases and Sciences
|
January 16, 2023
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission
Neeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
September 6, 2022
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study
Neeraj Narula, Emily C L Wong, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 28, 2025
Week 12 Reduction in MM-SES-CD is Predictive of Delayed Response to Upadacitinib in Crohn's disease
Emily C L Wong, Parambir S Dulai, John K Marshall, et al.
Page
of 21